Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 1.00 |
| ▸ | PI4KA | P42356 | 12/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 12/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.73 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.73 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GFER | P55789 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29646253 | 0.91 | PIK3CA (0.82) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL5532470 | 0.91 | PIK3CA (0.82) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL13862761 | 0.88 | PIK3CA (0.77) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL16296381 | 0.87 | PIK3CA (0.77) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL21091495 | 0.86 | PIK3CA (0.75) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL25218319 | 0.84 | PIK3CA (1.00) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL3306309 | 0.84 | PIK3CA (0.74) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL9722748 | 0.84 | PIK3CA (0.73) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL31114564 | 0.84 | MAPT (0.74) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL31114545 | 0.84 | PIK3CA (1.00) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INST NAT SANTE RECH MED (FR) | 2025-12-18 | — | — | US | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| EP-4460500-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118660885-A | Norbornene analogs and their use as potentiators of antitubercular drugs | 国家医疗保健研究所 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131649-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-13 | — | — | WO | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| CN-1023700-C | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents | PFIZER (US) | 1994-02-09 | — | — | CN | disclosed |
| US-5231173-A | DISAZO METAL CHELATE COMPOUNDS FOR OPTICAL RECORDING MEDIA | MITSUBISHI KASEI CORPORATION (JP) | 1993-07-27 | — | — | US | disclosed |
| EP-0343893-B1 | AROMATIC AND HETEROCYCLIC CARBOXAMIDE DERIVATIVES AS ANTINEOPLASTIC AGENTS | PFIZER INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5120872-A | Textile dyeing | CIBA-GEIGY CORPORATION (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0477373-A1 | METAL CHELATE COMPOUND AND OPTICAL RECORDING MEDIUM COMPRISING THE SAME | Mitsubishi Chemical Corporation (JP) | 1992-04-01 | — | — | EP | disclosed |
| US-4994563-A | Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | disclosed |
| US-4970318-A | ANTICARBINOGENIC AGENTS | PFIZER INC. (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0349486-A2 | Azo dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | disclosed |
| CN-1037898-A | The preparation of aromatics and Heterocyclylcarboxamderivatives derivatives antineoplastic agent | PFIZER (US) | 1989-12-13 | — | — | CN | disclosed |
| EP-0343893-A1 | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents | PFIZER INC. (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | PIK3CA 3635/4885PI4KA 3312/4885PI4KB 2535/4885 |
| US-20250382273-A1 | BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS | BBOX1, NDUFB6, NDUFB5 | PIK3CA 3378/4885PI4KA 4333/4885PI4KB 3022/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | PIK3CA 2650/4885PI4KA 1138/4885PI4KB 938/4885 |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | NSD3, NSD2, NSD1 | PIK3CA 3635/4885PI4KA 3312/4885PI4KB 2535/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | PIK3CA 4363/4885PI4KA 2500/4885PI4KB 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.